References
- Abbott JD, Ahmed HN, Vlachos HA, et al. Comparison of outcome in patients with ST-elevation versus non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2007;100:190-5
- Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81
- Mehta SR, Yusuf S, and the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Study Investigators, The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000;21:2033-41
- Sabatine MS, Cannon CP, Gibson CM, et al; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89
- Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005;366:1607-21
- Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
- Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005;142:251-9
- Weintraub WS, Mahoney EM, Lamy A, et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol 2005;45:838-45
- Mahoney EM, Mehta S, Yuan Y, et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J 2006;151:219-27
- Beinart SC, Kolm P, Veledar E, et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol 2005;46:761-9
- Cowper PA, Udayakumar K, Sketch MH Jr, et al. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. J Am Coll Cardiol 2005;45:369-76
- Mahoney EM, Wang K, Arnold SV, et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel thrombolysis in myocardial infarction (TRITON-TIMI 38). Circulation 2010;121:71-9
- Eli Lilly data on file. Eli Lilly’s analysis of i3 InVision Data Mart data from 2006 to mid-2008. October 2009. Available at: http://www.i3global.com
- Daiichi-Sankyo, Incorporated/Lilly Research Laboratories data on file. TRITON-TIMI 38 eight-country economic cohort data, Indianopolis, Indiana
- Tsai TT, Ho PM, Xu S, et al. Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent). Circ Cardiovasc Interv 2010;3:230-5
- Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33
- Peeters A, Mamun AA, Willekens F, et al. for NEDCOM. A cardiovascular life history: a life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002;23:458-66
- Mahoney EM, Jurkovitz CT, Chu H, et al. Cost and cost-effectiveness of an early invasive versus conservative strategy for the treatment of unstable angina and non-ST-segment-elevation myocardial infarction. JAMA 2002;288:1851-8
- Thomson PDR. Drug topics. Red Book for Windows. Version 61127, 58. Montvale, NJ: Thomson PDR, 2010
- US Department of Labor, Bureau of Labor Statistics. Consumer Price Index—all urban consumers (current series), 2010. http://data.bls.gov/PDQ/outside.jsp?survey=cu. Accessed March 29, 2011
- Yale Wasserman. Physicians’ fee reference, 28th edn. Milwaukee, WI: Yale Wasserman, DMD Medical Publishers Ltd, 2011
- Faulkner E, Mauskopf J, Bae J. Hospital contracting trends and implications for adoption and use of new health technologies. J Manag Care Med 2009;12:6-22
- Centers for Medicare and Medicaid Services. 42 CFR, parts 412, 413, 415, 485, and 489. Medicare program: changes to the hospital inpatient prospective payment systems for acute care hospitals and fiscal year 2010 rates; and changes to the long-term care hospital prospective payment system and rate years 2010 and 2009 rates. Fed Regist 2009;74. http://www.cms.gov/AcuteInpatientPPS/10FR/itemdetail.asp?filterType=none&filterByDID=-99&sortByDID=1&sortOrder=ascending&itemID=CMS1227461&intNumPerPage=10/. Accessed August 1, 2010